{"filing":{"accession_number":"0001599298-26-000078","cik":"0001599298","ticker":"SMMT","company_name":"Summit Therapeutics Inc.","form":"8-K","filing_date":"2026-09-14","report_date":"2026-09-13","primary_document":"smmt-20260913.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1599298/000159929826000078/smmt-20260913.htm"},"events":[{"id":33168,"run_id":30491,"accession_number":"0001599298-26-000078","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Summit disclosed that its partner Akeso announced updated overall survival data from the Phase III HARMONi-2 trial of ivonescimab, showing a statistically significant 27% reduction in risk of death (HR 0.73, p=0.009) and 8.2-month median OS improvement versus pembrolizumab. This represents a material clinical milestone for Summit's lead investigational asset, supporting its ongoing global Phase III HARMONi-7 program and FDA BLA filing (PDUFA date November 2026). While the event is operational/clinical rather than financial, governance, or legal in nature, it materially affects investor assessment of the company's pipeline prospects and regulatory pathway.","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-14","form":"8-K","submitted_at":null,"items":[{"id":36538,"accession_number":"0001599298-26-000078","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Summit disclosed that its partner Akeso announced updated overall survival data from the Phase III HARMONi-2 trial of ivonescimab, showing a statistically significant 27% reduction in risk of death (HR 0.73, p=0.009) and 8.2-month median OS improvement versus pembrolizumab. This represents a material clinical milestone for Summit's lead investigational asset, supporting its ongoing global Phase III HARMONi-7 program and FDA BLA filing (PDUFA date November 2026). While the event is operational/clinical rather than financial, governance, or legal in nature, it materially affects investor assessment of the company's pipeline prospects and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:38:53.364418+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36538,"accession_number":"0001599298-26-000078","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Summit disclosed that its partner Akeso announced updated overall survival data from the Phase III HARMONi-2 trial of ivonescimab, showing a statistically significant 27% reduction in risk of death (HR 0.73, p=0.009) and 8.2-month median OS improvement versus pembrolizumab. This represents a material clinical milestone for Summit's lead investigational asset, supporting its ongoing global Phase III HARMONi-7 program and FDA BLA filing (PDUFA date November 2026). While the event is operational/clinical rather than financial, governance, or legal in nature, it materially affects investor assessment of the company's pipeline prospects and regulatory pathway.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:38:53.364418+00:00","company_name":"Summit Therapeutics Inc.","ticker":"SMMT","filing_date":"2026-09-14"}]}